ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Another PP is on the way

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Feb 10, 2021 1:50pm

81 Views

Post# 32527147

RE:RE:Another PP is on the way

I mean what price do you think PP participant would like to pay? .12? .10? It could be only lower than last PP given PMN has no real developments. This reminds me the running up a few months ago when PMN announce the Covid story. Short lived pop is bubble, nothing else.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"